Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MGRM NASDAQ:OM NASDAQ:TELA NASDAQ:TLSI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMGRMMonogram Orthopaedics$5.75+0.3%$5.38$1.92▼$6.02$233.63M0.6994,410 shs76,582 shsOMOutset Medical$13.69-3.3%$15.53$5.85▼$25.35$243.22M2.14151,702 shs94,858 shsTELATELA Bio$1.58-2.5%$1.80$0.86▼$3.26$62.59M0.8481,197 shs39,397 shsTLSITriSalus Life Sciences$4.43-5.3%$4.65$3.42▼$5.88$220.91M0.49100,796 shs117,301 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMGRMMonogram Orthopaedics0.00%+0.70%+7.48%+116.17%+71.13%OMOutset Medical0.00%-2.28%+6.21%-31.41%+78.95%TELATELA Bio0.00%-0.63%-1.25%-7.06%-40.15%TLSITriSalus Life Sciences0.00%-11.22%+14.18%-14.64%-11.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMGRMMonogram Orthopaedics$5.75+0.3%$5.38$1.92▼$6.02$233.63M0.6994,410 shs76,582 shsOMOutset Medical$13.69-3.3%$15.53$5.85▼$25.35$243.22M2.14151,702 shs94,858 shsTELATELA Bio$1.58-2.5%$1.80$0.86▼$3.26$62.59M0.8481,197 shs39,397 shsTLSITriSalus Life Sciences$4.43-5.3%$4.65$3.42▼$5.88$220.91M0.49100,796 shs117,301 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMGRMMonogram Orthopaedics0.00%+0.70%+7.48%+116.17%+71.13%OMOutset Medical0.00%-2.28%+6.21%-31.41%+78.95%TELATELA Bio0.00%-0.63%-1.25%-7.06%-40.15%TLSITriSalus Life Sciences0.00%-11.22%+14.18%-14.64%-11.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMGRMMonogram Orthopaedics 3.50Strong Buy$5.40-6.09% DownsideOMOutset Medical 3.00Buy$24.6780.18% UpsideTELATELA Bio 2.50Moderate Buy$4.50184.81% UpsideTLSITriSalus Life Sciences 3.25Buy$10.75142.66% UpsideCurrent Analyst Ratings BreakdownLatest TELA, OM, TLSI, and MGRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025OMOutset MedicalRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSector Perform$22.008/7/2025OMOutset MedicalRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$21.00 ➝ $22.007/14/2025OMOutset MedicalBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$37.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMGRMMonogram OrthopaedicsN/AN/AN/AN/A$0.42 per shareN/AOMOutset Medical$113.69M2.14N/AN/A$7.49 per share1.83TELATELA Bio$69.30M0.90N/AN/A$0.72 per share2.19TLSITriSalus Life Sciences$35.99M6.14N/AN/A($0.83) per share-5.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMGRMMonogram Orthopaedics-$16.33M-$0.50N/AN/AN/AN/A-126.82%-96.87%11/13/2025 (Estimated)OMOutset Medical-$127.98M-$20.29N/A∞N/A-82.06%-97.17%-32.84%11/5/2025 (Estimated)TELATELA Bio-$37.84M-$1.12N/AN/AN/A-54.12%-329.48%-57.34%11/6/2025 (Estimated)TLSITriSalus Life Sciences-$30.05M-$1.18N/AN/AN/A-86.61%N/A-116.50%11/13/2025 (Estimated)Latest TELA, OM, TLSI, and MGRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025Q2 2025MGRMMonogram Orthopaedics-$0.11-$0.16-$0.05-$0.16N/AN/A8/12/2025Q2 2025TLSITriSalus Life Sciences-$0.22-$0.27-$0.05-$0.27$10.69 million$11.21 million8/11/2025Q2 2025TELATELA Bio-$0.18-$0.22-$0.04-$0.22$20.67 million$20.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMGRMMonogram OrthopaedicsN/AN/AN/AN/AN/AOMOutset MedicalN/AN/AN/AN/AN/ATELATELA BioN/AN/AN/AN/AN/ATLSITriSalus Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMGRMMonogram OrthopaedicsN/A2.162.16OMOutset Medical0.637.476.05TELATELA Bio4.143.192.59TLSITriSalus Life SciencesN/A4.083.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMGRMMonogram Orthopaedics0.45%OMOutset MedicalN/ATELATELA Bio94.35%TLSITriSalus Life Sciences2.58%Insider OwnershipCompanyInsider OwnershipMGRMMonogram Orthopaedics28.10%OMOutset Medical2.40%TELATELA Bio4.70%TLSITriSalus Life Sciences27.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMGRMMonogram Orthopaedics2840.63 million29.21 millionNot OptionableOMOutset Medical52017.77 million17.34 millionNot OptionableTELATELA Bio12039.62 million37.75 millionOptionableTLSITriSalus Life Sciences10649.87 million36.15 millionNot OptionableTELA, OM, TLSI, and MGRM HeadlinesRecent News About These CompaniesRoth Capital Issues Optimistic Outlook for TLSI EarningsAugust 19, 2025 | marketbeat.comFY2025 EPS Estimates for TLSI Raised by Cantor FitzgeraldAugust 17, 2025 | marketbeat.comNorthland Capmk Has Bearish Forecast for TLSI Q3 EarningsAugust 17, 2025 | marketbeat.comTriSalus Life Sciences (NASDAQ:TLSI) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPSAugust 14, 2025 | marketbeat.comTriSalus Life Sciences Reports Strong Growth Amid ChallengesAugust 14, 2025 | msn.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | msn.comTriSalus Life Sciences Reports Strong Q2 2025 GrowthAugust 13, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comTriSalus Life Sciences backs FY25 revenue growth view up 50%August 12, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue EstimatesAugust 12, 2025 | zacks.comTriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth ConferenceJuly 30, 2025 | businesswire.comTriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference CallJuly 29, 2025 | businesswire.comTriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred StockJuly 24, 2025 | businesswire.comTriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System - Business WireJune 25, 2025 | businesswire.comTriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital StructureJune 23, 2025 | businesswire.comTriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. PatienceMay 30, 2025 | businesswire.comJodi Devlin Sells 4,764 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) StockMay 22, 2025 | insidertrades.comTriSalus outlines at least 50% revenue growth for 2025 as new Medicare code expands addressable marketMay 15, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comTriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comTriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 GuidanceMay 15, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025Can AI Defense Contracts Push Palantir Shares Higher?By Chris Markoch | August 19, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Broadcom Named in Apple’s $100B U.S. Investment PlanBy Leo Miller | August 22, 2025Why BitMine’s Massive Discount Could Signal a Major OpportunityBy Jeffrey Neal Johnson | August 21, 2025TELA, OM, TLSI, and MGRM Company DescriptionsMonogram Orthopaedics NASDAQ:MGRM$5.75 +0.02 (+0.35%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.69 -0.06 (-1.04%) As of 09/12/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was founded in 2015 and is headquartered in Austin, Texas.Outset Medical NASDAQ:OM$13.69 -0.46 (-3.25%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$13.68 0.00 (-0.04%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.TELA Bio NASDAQ:TELA$1.58 -0.04 (-2.47%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.58 +0.00 (+0.32%) As of 09/12/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.TriSalus Life Sciences NASDAQ:TLSI$4.43 -0.25 (-5.34%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$4.43 0.00 (0.00%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
